Lonza Edges Into New Frontier With Singapore Cell Therapy Facility
This article was originally published in PharmAsia News
Executive SummarySINGAPORE - Swiss-based contract manufacturer Lonza marked the groundbreaking of its new $28.7 million cell therapy facility in Singapore Sept. 9
You may also be interested in...
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).